2024-09-10 - Analysis Report
##  MRK Stock Analysis:

**Company Overview:**  MRK, Merck & Co., Inc., is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

**1.  Performance vs. S&P 500 (VOO):**

* **Cumulative return (MRK):** 51.84%
* **Cumulative return (VOO):** 81.34%
* **Lagging behind VOO by:** 29.5% 
* **Relative lag:** 46.23% (meaning MRK's performance is in the 46.23rd percentile of its historical performance range compared to VOO).

**2. Recent Price Movement:**

* **Closing price:** $117.84
* **5-day moving average:** $117.45
* **20-day moving average:** $115.83
* **60-day moving average:** $121.80

**3. Technical Indicators:**

* **RSI:** 67.93 (indicates a potentially overbought condition)
* **PPO:** 0.53 (suggests a bullish momentum)
* **Delta_Previous_Relative_Divergence:** 2.21 (positive, indicates a recent short-term upward trend)
* **Expected_Return:** 10.33% (projected maximum 5-year return on investment)

**4. Recent Earnings and Outlook:**

| Date     | EPS     | Revenue         |
| -------- | -------- | ---------------- |
| 2024-08-05 | 2.15    | $16.11 B        |
| 2024-05-03 | 1.88    | $15.78 B        |
| 2023-11-03 | 1.87    | $15.96 B        |
| 2023-08-07 | -2.35   | $15.04 B        |
| 2024-08-05 | -2.35   | $15.04 B        |

* **Most recent earnings (2024-08-05):** Exceeded analysts' expectations.
* **Outlook:** Merck has a strong pipeline of new drugs and therapies, which could support continued growth in the future. 

**5. Overall Analysis:**

MRK has lagged behind the S&P 500 in recent years, but recent earnings have been strong and the company has a promising outlook. The technical indicators suggest a potential overbought condition, but also a short-term upward trend. Overall, MRK appears to be a strong company with a solid growth trajectory, though investors should be aware of the current high valuation.

**6. Report in English:**

## MRK Stock Analysis:

**Company Overview:** MRK, Merck & Co., Inc., is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative return (MRK):** 51.84%
* **Cumulative return (VOO):** 81.34%
* **Lagging behind VOO by:** 29.5% 
* **Relative lag:** 46.23% (meaning MRK's performance is in the 46.23rd percentile of its historical performance range compared to VOO).

**2. Recent Price Movement:**

* **Closing price:** $117.84
* **5-day moving average:** $117.45
* **20-day moving average:** $115.83
* **60-day moving average:** $121.80

**3. Technical Indicators:**

* **RSI:** 67.93 (indicates a potentially overbought condition)
* **PPO:** 0.53 (suggests a bullish momentum)
* **Delta_Previous_Relative_Divergence:** 2.21 (positive, indicates a recent short-term upward trend)
* **Expected_Return:** 10.33% (projected maximum 5-year return on investment)

**4. Recent Earnings and Outlook:**

| Date     | EPS     | Revenue         |
| -------- | -------- | ---------------- |
| 2024-08-05 | 2.15    | $16.11 B        |
| 2024-05-03 | 1.88    | $15.78 B        |
| 2023-11-03 | 1.87    | $15.96 B        |
| 2023-08-07 | -2.35   | $15.04 B        |
| 2024-08-05 | -2.35   | $15.04 B        |

* **Most recent earnings (2024-08-05):** Exceeded analysts' expectations.
* **Outlook:** Merck has a strong pipeline of new drugs and therapies, which could support continued growth in the future. 

**5. Overall Analysis:**

MRK has lagged behind the S&P 500 in recent years, but recent earnings have been strong and the company has a promising outlook. The technical indicators suggest a potential overbought condition, but also a short-term upward trend. Overall, MRK appears to be a strong company with a solid growth trajectory, though investors should be aware of the current high valuation. 
